Drugmaker Merck & Co., Inc. (
) on Thursday saw its earnings estimates boosted by analysts at
UBS, based on the introduction of its new hepatitis C treatment,
The firm said it raised its estimates for MRK through 2011,
while maintaining its "Buy" rating and $42 price target. That
target suggests a healthy 18% upside to the stock's Wednesday
closing price of $35.53.
Merck shares were mostly flat in premarket trading Thursday.
The Bottom Line
Shares of Merck (
) have a 4.28% dividend yield, based on last night's closing stock
price of $25.53. The stock has technical support in the $32 price
area. If the shares can firm up, we see overhead resistance around
the $37-$38 price levels.
Merck & Co., Inc. (
) is not recommended at this time, holding a Dividend.com DARS™
Rating of 3.4 out of 5 stars.
Be sure to visit our complete recommended list of the
Best Dividend Stocks
, as well as a detailed explanation of
our ratings system here